Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monobenzone plus imiquimod for cutaneous melanoma metastases
NL-OMON25340Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monobenzone and imiquimod in melanoma and cutaneous melanoma (CM), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical signs of cutaneous tumor regression at MI treatment site. Started Mar 2011; status: recruiting.
02
Drugs
monobenzoneimiquimod
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON25340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25340.